signal regulatory protein beta 3, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SIRPB3P profile across patient tissues and cancer cell-line models. SIRPB3P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SIRPB3P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SIRPB3P RNA expression shows 12,059 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight SKCM, KIRC, and ESCA as cancer lineages where SIRPB3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIRPB3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIRPB3P survival associations across molecular data types. SIRPB3P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIRPB3P RNA expression–survival associations across cancer types. High SIRPB3P expression shows unfavorable associations in KIRC and KIRP, but favorable associations in SKCM, PAAD, LGG and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SIRPB3P RNA expression.
This table summarizes SIRPB3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SIRPB3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIRPB3P shows lower tumor expression in BRCA and higher tumor expression in KIRC, LUAD, HNSC, ESCA and STAD. The KIRC box plot shows higher SIRPB3P RNA expression in tumor versus normal tissue (log2 FC = +0.402, t-test p < 0.001).
This table shows molecular features associated with SIRPB3P in patient tissues and cancer cell lines. In patient samples, SIRPB3P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
